A Study to Evaluate Pharmacokinetics (PK) and Safety of Inaxaplin in Participants With Renal Impairment

• Status: Not yet recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the pharmacokinetics and safety of a single dose of Inaxaplin (IXP) in participants with severe renal impairment and healthy participants with normal renal function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Vertex Pharmaceuticals Incorporated

Criteria

Key Inclusion Criteria:

• Body mass index (BMI) of 18.5 to 40.0 kilogram per meter square (kg/m^2)

• Stable renal function for at least 1 month prior to enrollment

Key Exclusion Criteria:

• Uncontrolled hypertension

• Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.